A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients

Trial Profile

A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2017 Status changed from recruiting to discontinued according to results published in the Pediatric Transplantation.
    • 03 May 2017 Results presented at the 2017 American Transplant Congress
    • 12 Sep 2016 This trial was completed in Belgium, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top